|
|
R&D Productivity - Measures of Success in the Pharmaceutical IndustryPublished by: Decision Resources Published: Sep. 27, 2006 - 24 Pages Price reduced due to age.Table of Contents
AbstractUnder pressure to improve R&D productivity and decrease product time to market, pharmaceutical companies are implementing new strategies, and biotech is playing a prominent role. In this report, we assess multiple measures of R&D success and then look at successful companies to see what has worked for them and what has not.Get the Answers You Need to Shape Your Strategy The pharmaceutical industry's R&D expenditure has increased steadily in the last ten years. Exactly how much are big pharma companies spending? Does major R&D investment guarantee success? What are the measures that most accurately assess R&D productivity? To increase R&D productivity, big pharma needs to create new drug development models. Must the nearly total emphasis on potential blockbusters be abandoned? How can the development of targeted, smallmarket drugs and biological agents, long ignored, contribute to R&D success? What part will biotech play? Big pharma has long depended on the biotech industry to keep its product pipelines full, but biotech is maturing and developing new business models. What are they, and how can pharmaceutical companies benefi t from new ways of doing business with biotech? Several big pharma companies have already made major changes in their own R&D organizations and in their relationships with biotech companies. What are these innovations, and are they working well so far? What do they imply for the future of both the pharmaceutical and biotech industries? Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||